SCHEMBL403044

SCHEMBL403044

O=C(O)c1ccc2c(=O)[nH]c(Cc3ccccc3F)nc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
RECQL P46063 1/20 0.62
POLB P06746 1/20 0.62
PDE5A O76074 1/20 0.61
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
PARP1 P09874 3/20 0.44
PARP2 Q9UGN5 1/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RAB9A P51151 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401505 0.91 PDE5A (0.62) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL2119052 0.88 POLB (0.51) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL405888 0.87 KDM4E (0.61) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL404586 0.87 KDM4E (0.61) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL401473 0.87 KDM4E (0.64) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL17900820 0.87 KDM4E (0.64) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL400622 0.87 PDE5A (0.65) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL400692 0.86 PDE5A (0.68) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL404893 0.86 PDE5A (0.64) KDM4ERECQLPOLBPDE5ALMNA
SCHEMBL406054 0.86 KDM4E (0.62) KDM4ERECQLPOLBPDE5ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
CN-101557826-A Therapeutic agent for urinary tract disease ASKA PHARM CO LTD (JP) 2009-10-14 CN disclosed
CN-101501007-A Quinazoline derivative ASKA PARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD KDM4E 4291/4885RECQL 878/4885POLB 555/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A KDM4E 2869/4885RECQL 100/4885POLB 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.